Should You Retain Your Conviction in Rocket Pharmaceuticals (RCKT)?
Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here.
Rocket Pharmaceuticals Inc. (RCKT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Maverick Capital Lee Ainslie | 3,888,312 | $104,751,125 | -4% | 1.96% |
| 2. | Citadel Investment Group Ken Griffin | 2,469,813 | $66,536,762 | +1% | 0.01% |
| 3. | Perceptive Advisors Joseph Edelman | 1,801,068 | $48,520,772 | +6% | 0.84% |
| 4. | Logos Capital Arsani William | 1,300,000 | $35,022,000 | +2% | 2.83% |
| 5. | VenBio Select Advisor Kurt Von Emster | 1,260,900 | $33,968,646 | 0.39% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.75 | 1,355,932 | Large Shareholder, Director, Other | 17,628,567 | 2022-10-06 | Filing | |
| $17.34 | 22,000 | 517,639 | 2022-02-07 | Filing | ||
| $56.00 | 247,720 | Large Shareholder, Director | 17,530,044 | 2020-12-10 | Filing | |
| $9.50 | 1,000 | 6,675 | 2020-03-18 | Filing | ||
| $22.25 | 225,000 | Large Shareholder, Director | 17,282,324 | 2019-12-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $28.43 | 274,000 | 365,912 | 2024-03-21 | Filing | ||
| $23.35 | 1,079 | 53,327 | 2024-05-16 | Filing | ||
| $23.35 | 9,790 | 728,069 | 2024-05-16 | Filing | ||
| $23.35 | 1,048 | 65,762 | 2024-05-16 | Filing | ||
| $23.35 | 4,046 | 400,972 | 2024-05-16 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 17,687,772 | $530,102,527 | 8.28% | |
| 2. | 8,197,546 | $245,680,453 | 0.04% | |
| 3. | 5,930,178 | $177,727,435 | 0% | |
| 4. | 5,447,565 | $163,263,523 | 0% | |
| 5. | 3,941,859 | $118,137,514 | 0.68% |
News See All
15 Best Strong Buy Stocks To Invest In
In this piece, we will take a look at the 15 best strong buy stocks to invest in.
Should You Maintain Your Conviction in Rocket Pharmaceuticals (RCKT)?
Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here.
11 Most Promising Biotech Stocks to Buy According to Analysts
In this article, we will take a look at the 11 most promising biotech stocks to buy according to analysts.
Billionaire Lee Ainslie's Top 10 Stock Picks
Hedge fund managers are known for investing in various asset classes in the race to unlock value in the market.
Should You Hold Rocket Pharmaceuticals (RCKT)?
Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2023 investor letter. A copy of the same can be downloaded here.
10 Oversold Biotech Stocks to Buy
In this article, we will take a look at the 10 oversold biotech stocks to buy.
12 Stocks with Biggest Upside Potential According to Analysts
In this article, we will take a look at the 12 stocks with biggest upside potential according to analysts.
Here’s Why Rocket Pharmaceuticals (RCKT) Stock Suffered in Q1
Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2023 investor letter. A copy of the same can be downloaded here.
What Makes Rocket Pharmaceuticals (RCKT) Shares Attractive?
Baron Funds, an investment management company, released its “Baron Opportunity Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here.
Billionaire Hedge Funds
